Metrics to compare | 688221 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship688221PeersSector | |
|---|---|---|---|---|
P/E Ratio | −121.3x | −2.3x | −0.2x | |
PEG Ratio | −1.58 | 0.06 | 0.00 | |
Price/Book | 4.5x | 4.3x | 2.6x | |
Price / LTM Sales | 12.1x | 10.2x | 2.7x | |
Upside (Analyst Target) | - | 90.2% | 69.6% | |
Fair Value Upside | Unlock | 15.3% | 11.7% | Unlock |
Frontier Biotechnologies Inc., a commercial-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes various medicines that improve patients’ health in China. It offers Aikening, an IV fusion inhibitor for dual therapy of HIV-1. The company’s pipeline products include FB2004 indicated for HBV; FB7011 and FB7013 for IgA nephropathy; FB7012 to treat hyperuricemia and gout; FB7041 to treat tumors; FB7024 for the treatment of hyperlipidemia; FB7023 to treat ASCVD; FB7033 for the treatment of MASH; FB4001 for osteoporosis; and FB3002 for pain management. Frontier Biotechnologies Inc. was founded in 2002 and is headquartered in Nanjing, China.